Celltech Group (NYSE: CLL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Nealon who started this subject	1/7/2004 7:20:49 AM
From: nigel bates	of 123

TEL AVIV, Jan 7 (Reuters) - Israel's Teva Pharmaceutical Industries said on Wednesday it received approval from the U.S. Food and Drug Administration for Metolazone tablets in 2.5 mg and 10 mg strengths. Metolazone tablets are the generic equivalent of Celltech (LSE: CCH.L - news - msgs) 's Zaroxolyn tablets, for the treatment of edema and hypertension, Teva said in a statement to the Tel Aviv Stock Exchange. Annual sales of these strengths of the brand product are approximately $40 million, Teva said...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next